EUVIMEDEUVIMED entdecken
Kohortenstudie

Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study

Abi Manesh, Priyanka Gautam, Selwyn Selva Kumar D, Pavithra Mannam, Anitha Jasper, Karthik Gunasekaran, Naveen Cherian Thomas, Rohit Ninan Benjamin, Leeberk Raja Inbaraj, Emily Devasagayam, Mithun Mohan George, Rajiv Karthik und 8 weitere

Clinical Infectious Diseases · 17.11.2023 · 77 (10) · 1460-1467

DOI: 10.1093/cid/ciad401 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 05.07.2023. Verfasst von Abi Manesh und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India. Hauptthemen laut MEDLINE: Persons with Disabilities, Infliximab, Tuberculosis, Central Nervous System. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Few treatment options exist for patients with severe central nervous system (CNS) tuberculosis (TB) worsening due to inflammatory lesions, despite optimal antitubercular therapy (ATT) and steroids. Data regarding the efficacy and safety of infliximab in these patients are sparse.

Methods

We performed a matched retrospective cohort study based on Medical Research Council (MRC) grading system and modified Rankin Scale (mRS) scores comparing 2 groups of adults with CNS TB. Cohort A received at least 1 dose of infliximab after optimal ATT and steroids between March 2019 and July 2022. Cohort B received only ATT and steroids. Disability-free survival (mRS score ≤2) at 6 months was the primary outcome.

Results

Baseline MRC grades and mRS scores were similar between the cohorts. Median duration before initiation of infliximab therapy from start of ATT and steroids was 6 (IQR: 3.7–13) months and for neurological deficits was 4 (IQR: 2–6.2) months. Indications for infliximab were symptomatic tuberculomas (20/30; 66.7%), spinal cord involvement with paraparesis (8/30; 26.7%), and optochiasmatic arachnoiditis (3/30; 10%), worsening despite adequate ATT and steroids. Severe disability (5/30 [16.7%] and 21/60 [35%]) and all-cause mortality (2/30 [6.7%] and 13/60 [21.7%]) at 6 months were lower in cohort A versus cohort B, respectively. In the combined study population, only exposure to infliximab was positively associated (aRR: 6.2; 95% CI: 2.18–17.83; P = .001) with disability-free survival at 6 months. There were no clear infliximab-related side effects noted.

Conclusions

Infliximab may be an effective and safe adjunctive strategy among severely disabled patients with CNS TB not improving despite optimal ATT and steroids. Adequately powered phase 3 clinical trials are required to confirm these early findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Persons with DisabilitiesInfliximabTuberculosis, Central Nervous SystemAdultHumansAntitubercular AgentsRetrospective StudiesSteroidsTreatment Outcome

Stichwörter der Autor:innen

CNS tuberculosisTNF-α inhibitordisability-free survivalinfliximab

Substanzen

Antitubercular AgentsInfliximabSteroids

Autor:innen und Institutionen

  • Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.
  • Department of Radiology, Christian Medical College, Vellore, Tamil Nadu, India.
  • Department of Internal Medicine, Christian Medical College, Vellore, Tamil Nadu, India.
  • Department of Physical Medicine and Rehabilitation, Christian Medical College, Vellore, Tamil Nadu, India.
  • Department of Neurology, Christian Medical College, Vellore, Tamil Nadu, India.
  • Department of Clinical Research, ICMR-National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India.

Zitieren

APA

Manesh, A., Gautam, P., Kumar D, S. S., Mannam, P., Jasper, A., Gunasekaran, K., Thomas, N. C., Benjamin, R. N., Inbaraj, L. R., Devasagayam, E., George, M. M., Karthik, R., Abraham, O. C., Vanjare, H. A., Sivadasan, A., Appaswamy, P. T., Jonathan, E., Michael, J. S., Samuel, P., & Varghese, G. M. (2023). Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study. Clinical Infectious Diseases, 77(10), 1460-1467. https://doi.org/10.1093/cid/ciad401

Vancouver

Manesh A, Gautam P, Kumar D SS, Mannam P, Jasper A, Gunasekaran K, et al. Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study. Clinical Infectious Diseases. 2023;77(10):1460-1467. doi:10.1093/cid/ciad401

BibTeX
@article{Manesh2023,
  author = {Manesh, Abi and Gautam, Priyanka and Kumar D, Selwyn Selva and Mannam, Pavithra and Jasper, Anitha and Gunasekaran, Karthik and Thomas, Naveen Cherian and Benjamin, Rohit Ninan and Inbaraj, Leeberk Raja and Devasagayam, Emily and George, Mithun Mohan and Karthik, Rajiv and Abraham, Ooriapadickal Cherian and Vanjare, Harshad A and Sivadasan, Ajith and Appaswamy, Prabhakar Thirumal and Jonathan, Edmond and Michael, Joy S and Samuel, Prasanna and Varghese, George M},
  title = {Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {10},
  pages = {1460--1467},
  doi = {10.1093/cid/ciad401}
}
Kostenlos starten →